Regencell Bioscience Holdings Ltd (RGC) Fair Value & Analysis
Healthcare · US · Market cap $2.5B · ISIN KYG7487R1002
What is Regencell Bioscience Holdings Ltd really worth?
Regencell Bioscience Holdings Ltd
RGC · US
Below-average quality, and trading another 148% above our fair value of $2.22.
Risks
Fair value as of: Aug 19, 2026
From 3 valuation models · updated 12 days ago
Share price −10.8% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($2.44). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
60‑month range $0.0843 – $78.00 · fair‑value band $2.06 – $2.44 · the $5.51 price screens above the $2.22 fair value. Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Regencell Bioscience Holdings Ltd (RGC) currently trades at $5.51, while our model-based Fair Value estimate is $2.22, implying the stock looks roughly 148.2% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 3 models at a data quality of 95/100, which puts the evidence level at low.
The balance sheet holds a net cash position of $1.9M. Fundamentals as of Aug 19, 2026
Our scenario range runs from $2.06 (bear case) to $2.44 (bull case); at $5.51, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −60%, RGC screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 3 models by family
Widest divergence: Dividend Discount ($2.69) versus Asset-Based ($0.0100). Highest evidence: Gordon GGM (69).
Notify me when RGC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 0
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Full company description
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2025 · reported fiscal years
Regencell Bioscience Holdings Ltd reported revenue of $0 in FY2024 versus $0 in FY2020. Reported net income was −$3.6M in FY2025.
RGC screens 148% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 636 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $37.92 | $15.33 | −60% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.52 | $104.88 | +35% |
| Hansoh Pharmaceutical Group 3692 | HK$33.50 | HK$16.14 | −52% |
Compare Regencell Bioscience Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Regencell Bioscience Holdings Ltd (RGC) overvalued or undervalued?
What is the fair value of RGC?
What is the quality score of RGC?
What is the net profit margin of RGC?
Does Regencell Bioscience Holdings Ltd pay a dividend?
Watch Regencell Bioscience Holdings Ltd in the live analysis
One click puts Regencell Bioscience Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.